Global Operations

Samsung Biologics Launches $1.8 Billion Bid for Swiss Peptide CDMO PolyPeptide

The purchase would give Samsung a global peptide manufacturing network to tap rising demand from GLP‑1 therapies, subject to regulatory, shareholder approval.